Latest News

Stocks in Play

Dividend Stocks

Breakout Stocks

Tech Insider

CAD Daily Briefing

US Markets

Stocks To Watch

The Week Ahead



Commodity News

Metals & Mining News

Crude Oil News

Crypto News

M & A News


OTC Company News

TSX Company News

Earnings Announcements

Dividend Announcements

Breakthrough Innovations Reshaping Recreational and Medicinal Cannabis Offerings

With cannabis legalization around the corner in Canada, coming in the months ahead, many of the brightest minds in the fields of horticulture and pharma are flocking to the sector to offer their hand at game-changing offerings for tomorrow’s consumers, complete with novel delivery methods that were unthinkable in years past.

R&D is ramping up, as the sector prepares to employ more people than the US manufacturing sector by 2020. Likewise, consumers of cannabis products will have a plethora of offerings to choose from, both in the medical and recreational realms.

Among the leaders in cannabis product innovation are a group that includes AXIM Biotechnologies, Inc. (OTC: AXIM), The Hydropothecary Corporation (TSX.V: THCX) (OTC: HYYDF), GW Pharmaceuticals plc (NASDAQ: GWPH), Novartis AG (NYSE: NVS) and Lifestyle Delivery Systems Inc. (CSE: LDS) (OTC: LDSYF).

Several companies in the space are branching out from just the one-dimensional role as growers, and are bolstering their offerings through extraction technology that leads to pharmaceuticals, specialty organic matter, and novel delivery methods.

Vancouver-based Lifestyle Delivery Systems is a prime example of a multi-faceted developer, focussed on specialized cultivation, as well as its proprietary CannaStripsTM product designed to deliver a controlled dosage within 90 seconds on a dissolving strip on the tongue, like a breath strip.

Since not all consumers new and experienced are going to desire the typical organic plant matter, including those who are uncomfortable with smoking it, the market is already welcoming everything from LDS’s CannaStripsTM, to chewing gums, to mist sprays, to pills, to hospital-grade pharmaceuticals.

As the cannabis market evolves, developers such as AXIM Biotechnologies, Inc. (OTC: AXIM), The Hydropothecary Corporation (TSX.V: THCX) (OTC: HYYDF), GW Pharmaceuticals plc (NASDAQ: GWPH), Novartis AG (NYSE: NVS) and Lifestyle Delivery Systems Inc. (CSE: LDS) (OTC: LDSYF) will benefit greatly from thinking outside the box.


While medicinal marijuana has been legal in Canada for years, the incoming legalization of cannabis for adult recreational use opens up the opportunities for all types of products.One novel method being presented by AXIM Biotechnologies is a cannabis chewing gum. Dubbed CanChew+™ and MedChew®, AXIM’s products are set for international release, including a recent preliminary distribution deal to sell products in South Korea. With industrial hemp-derived CBD, CanChew is legal in all 50 states of the USA.

Alternative cannabinoid delivery has become a serious business for The Hydropothecary Corporation. Based out of Quebec, Hydropothecary sells everything from cannabis oil sublingual mists, to ready-to-consume activated marijuana powder in capsule form.

The concept of cannabinoids in pill form isn’t new, but it’s appealing from the medicinal side of the sector. Pharmaceutical developers GW Pharmaceuticals plc (NASDAQ: GWPH) and Novartis AG (NYSE: NVS) are both taking a serious approach to cannabinoid delivery.

GW is heavily invested in a cannabis oil drug designed to treat epilepsy called “Epidiolex”. The company is optimistic in the upcoming cannabis oil market, and its usefulness as a medicine. The NDA filing for Epidiolex was accepted in late December.

Whereas, Novartis is relatively new to the scene, as its involvement comes through its Canadian subsidiary of its generic pharmaceuticals and biosimilar wing, called Sandoz Canada. Recently Sandoz formed a strategic alliance with private medical cannabis supplier Tilray. The terms of the deal have not yet been determined, however it’s likely that the deal will use Novartis’s channels to deliver Tilray’s cannabis capsules.

Sandoz spokesperson Isabelle Troitzky described the implication of the deal to in-Pharma Technologist, saying: “Once the alliance is in effect, initially, Tilray capsules and ingestible oil products will be offered for sale under doctor’s authorization directly to patients in Canada via mail order, as this is the current process in Canada. Subject to future regulatory changes, Sandoz Canada will wholesale and distribute co-branded – Sandoz and Tilray – non-smokable/non-combustible medical cannabis products to Canadian hospitals and pharmacies.”

Tilray’s product doesn’t currently have drug identification numbers (DINs), because they don’t make any therapeutic claims on the lable. However, it’s likely that Novartis’s involvement will move the product closer to Health Canada approval.

Whether a big-pharma deal could come down the pipeline for a product such as the CannaStrips™ brand dissolving strips from Lifestyle Delivery Systems, or the gums, mists, or capsules of the others is yet to be seen. At the moment, it appears the perfect balance of dosage and efficacy is coming from Lifestyle Delivery Systems’ CannaStripsTM.


Since forming in 2010, Lifestyle Delivery Systems Inc (CSE: LDS) (OTC: LDSYF) has targeted cannabinoid innovation—Resulting a plethora of new products and cultivation methods.

Aggressive investment in research and development led to a breakthrough delivery method. When LDS came out with CannaStripsTM, it was the first to put forth a sub-lingual strip not unlike breath strips, that quickly dissolve under the tongue to deliver pure cannabis to the patient without the harmful effects of smoking the plant.

LDS CEO, Brad Eckenweiler, has said, “We strongly believe that the CannaStripsTM delivery system is so unique that with clinical trials from a recognized health organization to substantiate the efficacy of the technology it would have to be at the top of the list of preferred delivery solutions anywhere in the world.”

The product is being ramped up for distribution in North America, the UK, and EU, having recently filed an enhanced provisional patent for the product in the latter two regions.

What’s possibly most unique about CannaStrips is how the company addressed the problem of consistent edible cannabis dosing. LDS has successfully cracked a code to develop a product, guaranteed to deliver equal doses and distribution of the active ingredients—So much so, that even cutting CannaStrips down the middle divides the dose equally. This kind of consistent dosing is incredibly rare in this industry, which for gives consumers peace of mind that they haven’t had before with cannabis edibles.

LDS are specialty growers of cannabis plants at their $6 million facility in Adelanto, California. It’s one of the few fully vertically integrated medical cannabis companies in California. The company has also become marketing and distributing its luxury brand of cannabis products called Rêveur for the California market.

The new product line, Rêveur (French for “dreamer”), is designed for the upscale luxury cannabis market using only fresh frozen organically grown cannabis strains processed at minus 50 degrees Celsius. Lifestyle Delivery Systems is an innovator in the field, with a serious goal towards developing better products for the emerging cannabis consumer market.


AXIM Biotechnologies, Inc. (OTC: AXIM)

AXIM is a biotechnology company, focusing on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoids based products. It also focuses on the research, development, and production of pharmaceutical, nutraceutical, oral health, and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. AXIM Biotechnologies, Inc. was founded in 2010 and is based in New York.

GW Pharmaceuticals plc (NASDAQ: GWPH)

GW is a biopharmaceutical company, engaging in discovering, developing, and commercializing cannabinoid prescription medicines derived from the Cannabis plant. GW markets Sativex, for the treatment of spasticity due to multiple sclerosis, which is also in Phase II trials for neuropathic pain. Their product pipeline includes Epidiolex, which is in Phase III clinical development to treat dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms. GW Pharmaceuticals plc was founded in 1998 and is based in the UK.

The Hydropothecary Corporation (TSX.V: THCX) (OTC: HYYDF)

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada). Hydropothecary creates award-winning innovative, easy to use and easy to understand products. With industry-leading cash cost per gram of $0.89, Hydropothecary is one of the lowest cost producers in the country. The first licensed producer in Quebec, the Company is headquartered in Quebec.

Novartis AG (NYSE: NVS)

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

For a more in-depth look into Lifestyle Delivery Systems you can view the in-depth report at USA News Group:

USA News Group
[email protected]

Legal Disclaimer/Disclosure:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Lifestyle Delivery Systems advertising and digital media. There may be other 3rd parties who may have shares in LDS, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.